Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2025-12-31 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于提前终止奋斗者二号员工持股计划的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the early termination of an employee stock ownership plan (奋斗者二号员工持股计划) by 健帆生物科技集团股份有限公司. It details the background, approval process, and impact of the termination. The document does not contain financial statements or detailed financial data but is a corporate announcement about a specific employee incentive plan. It is not an annual report, interim report, earnings release, or any other financial report. It is also not a regulatory filing about share transactions or board changes. The content fits best with a Capital/Financing Update (CAP) as it relates to changes in employee stock ownership plans, which affect company capital structure and financing arrangements. The document length is 2365 characters, which is relatively short but contains substantive information about the plan termination rather than just a notice of report publication or certification. Therefore, the most appropriate classification is CAP with high confidence.
2025-12-31 Chinese
奋斗者一号员工持股计划第二次持有人会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement regarding the resolution of a shareholders' meeting related to an employee stock ownership plan. It details the meeting attendance, voting results, and decisions made, specifically about the early termination of the employee stock ownership plan. There is no financial report, audit, or earnings data presented. The document is a formal announcement of voting results from a meeting of holders of the employee stock plan. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation.
2025-12-31 Chinese
关于增加2025年度日常关联交易预计的公告
Board/Management Information Classification · 95% confidence The document is an announcement from a company regarding an increase in the estimated amount of daily related party transactions for the fiscal year 2025. It details board meeting resolutions, transaction categories, related parties, pricing principles, and the impact on the company. The document is a formal disclosure of corporate governance and related party transaction updates, not a financial report or earnings release. It is not a full annual or interim report, nor is it a call transcript or audit report. It is also not a voting result or capital change announcement. The content fits best under Board/Management Information (MANG) as it involves board meeting decisions and disclosures about related party transactions approved by the board and independent directors. The document length is under 5,000 characters, but it contains substantive information about board resolutions, so it is not merely a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2025-12-24 Chinese
关于向参股子公司增资暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a capital increase (增资) to an associate subsidiary and related party transaction by 健帆生物科技集团股份有限公司. It details the board meeting approval, transaction overview, shareholding structure before and after the capital increase, financial data of the subsidiary and related parties, and compliance with regulatory requirements. The document is a formal disclosure of a financing-related transaction involving capital injection into a subsidiary, which affects the company's capital structure. It is not a full financial report, earnings release, or management discussion, but a specific update on a capital/financing event. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (5388 characters) and detailed content support this classification with high confidence.
2025-12-24 Chinese
第五届董事会第三十七次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at the 37th meeting of the 5th Board of Directors of the company. It details the meeting attendance, the agenda items discussed, voting results, and references to related announcements on a regulatory disclosure website. The content focuses on board decisions, including related party transactions and capital increases, and includes statements about compliance with company law and articles of association. There is no financial report, audit, or earnings data presented. The document is clearly a Board/Management Information announcement about board meeting resolutions and decisions.
2025-12-24 Chinese
2025年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2025 first extraordinary general meeting (临时股东大会) of the company 健帆生物科技集团股份有限公司. It includes information about the meeting date, attendance, voting results on various proposals, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the official voting results and decisions made by shareholders during the meeting. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is not a presentation or a proxy solicitation but an official announcement of voting results from a shareholders' meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is sufficient and contains substantive voting data, not just a brief notice or a report publication announcement.
2025-12-11 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.